No black box warning on record for Rapiblyk

As of the latest FDA labeling reviewed, Rapiblyk (LANDIOLOL) does not carry a black box warning. Standard warnings and precautions still apply — see the full Rapiblyk medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Risk of hypotension, bradycardia, and cardiac failure: Monitor for signs and symptoms of cardiovascular adverse effects. Reduce or discontinue use ( 5.1 , 5.2 , 5.3 ) Risk of exacerbating reactive airway disease ( 5.5 ) Diabetes mellitus: May mask symptoms of hypoglycemia and alter glucose levels; monitor ( 5.6 ) Monitor for signs of myocardial ischemia when abruptly dis

No black box warning on record for Rapiblyk

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Risk of hypotension, bradycardia, and cardiac failure: Monitor for signs and symptoms of cardiovascular adverse effects. Reduce or discontinue use ( 5.1 , 5.2 , 5.3 ) Risk of exacerbating reactive airway disease ( 5.5 ) Diabetes mellitus: May mask symptoms of hypoglycemia and alter glucose levels; monitor ( 5.6 ) Monitor for signs of myocardial ischemia when abruptly dis

Rapiblyk Black Box Warning

No black box warning on record for Rapiblyk

Other warnings & precautions

Rapiblyk Black Box Warning

No black box warning on record for Rapiblyk

Other warnings & precautions